Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson Sells 9,221 Shares

Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson sold 9,221 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $31.50, for a total transaction of $290,461.50. Following the sale, the executive vice president now owns 59,730 shares of the company’s stock, valued at approximately $1,881,495. The trade was a 13.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Alkermes Trading Up 0.9 %

Shares of Alkermes stock opened at $31.46 on Friday. The company’s 50-day moving average price is $28.32 and its 200-day moving average price is $26.75. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $32.88. The company has a market cap of $5.09 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 1.03 and a beta of 0.49.

Institutional Trading of Alkermes

Several institutional investors and hedge funds have recently bought and sold shares of the company. Pacer Advisors Inc. grew its position in shares of Alkermes by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 5,640,642 shares of the company’s stock valued at $135,939,000 after purchasing an additional 1,362,079 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Alkermes by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,884,012 shares of the company’s stock worth $69,507,000 after buying an additional 371,039 shares in the last quarter. Armistice Capital LLC increased its stake in Alkermes by 301.5% in the 2nd quarter. Armistice Capital LLC now owns 2,699,179 shares of the company’s stock worth $65,050,000 after acquiring an additional 2,026,961 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Alkermes by 87.1% in the 2nd quarter. American Century Companies Inc. now owns 2,203,456 shares of the company’s stock valued at $53,103,000 after acquiring an additional 1,025,905 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its position in shares of Alkermes by 365.5% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company’s stock valued at $52,704,000 after acquiring an additional 1,478,422 shares during the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ALKS has been the subject of several research reports. The Goldman Sachs Group decreased their target price on Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, October 25th. HC Wainwright reiterated a “neutral” rating and set a $37.00 price target on shares of Alkermes in a research note on Friday, October 25th. Cantor Fitzgerald lowered their price objective on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. cut their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and lifted their target price for the stock from $25.00 to $36.00 in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $35.42.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.